Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03067051
Recruitment Status : Unknown
Verified May 2019 by SpectraCure AB.
Recruitment status was:  Recruiting
First Posted : March 1, 2017
Last Update Posted : May 13, 2019
Information provided by (Responsible Party):
SpectraCure AB

Brief Summary:
The rationale for the study is to obtain safety data as well as to establish dose parameters for the SpectraCure P18 System with IDOSE®, with verteporfin for injection (VFI) as photosensitizer for the treatment of recurrent prostate cancer.

Condition or disease Intervention/treatment Phase
Recurrent Prostate Cancer Drug: Verteporfin Device: SpectraCure P18 System Phase 1

Detailed Description:

In 2011, more than 200,000 men in North America alone were diagnosed with cancer of the prostate, which makes it one of the most common cancer types. It affects the lives of the subjects in many ways.

After treatment the subjects PSA levels are being closely monitored to detect potential recurrence. A high number of subjects will get recurrent prostate cancer. The treatment options for recurrent cancer are more limited than for primary tumors as secondary treatment partly depends on which treatment the subject has previously undergone.

Treatment of recurrent prostate cancer may, depending on the standard treatment of the primary disease, include the following:

Radiation therapy.

  • Prostatectomy for subjects initially treated with radiation therapy.
  • Hormone therapy.
  • Pain medication, external radiation therapy, internal radiation therapy with radioisotopes such as strontium-89, or other treatments as palliative therapy to lessen bone pain.

The objectives of this study is to demonstrate that the use of the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software) and verteporfin for injection (VFI) is a safe treatment for recurrent prostate cancer.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Intervention Model: Sequential Assignment
Intervention Model Description: As result of the accelerated titration design with light dose and verteporfin for injection (VFI), the final number of subjects depends on the outcome of the titration. If all dose levels enroll and complete at the minimum number of subjects, the number of subjects is 12 (1 each at dose levels 1-3, 3 each at dose levels 4-6). If all dose levels enroll and complete at the maximum number of subjects, the number of subjects is 36 (6 subjects at each dose level 1-6). The range is thus 12-36 subjects.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-label Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System (Interstitial Multiple Diode Lasers and IDOSE® Software) and Verteporfin for Injection (VFI) for the Treatment of Recurrent Prostate Cancer
Actual Study Start Date : March 21, 2017
Estimated Primary Completion Date : December 31, 2019
Estimated Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
Drug Information available for: Verteporfin

Arm Intervention/treatment
Experimental: PDT and verteporfin dose finding

Verteporfin and Interstitial Photodynamic Therapy are the interventions in this dose titration study.

The interventions will be light dose (as laser) using the SpectraCure P18 System and drug intervention with verteporfin as a photosensitizer.

The study will be conducted as a dose titration study to determine the light and drug threshold dose using the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software) and verteporfin for injection (VFI).

The light is delivered to the tumor via optical fibers and each dose arm will receive Interventional Photodynamic Therapy of Prostate Cancer combined with the drug verteporfin as a photosensitizer .

Drug: Verteporfin
In the last decade a clinical interest of developing new methods for minimally invasive treatments of organ-confined prostatic malignancies has been pursued. In this study the drug verteporfin for injection (VFI) is to be used with the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software).
Other Name: Visudyne

Device: SpectraCure P18 System
Interstitial Photodynamic therapy is provided with the the SpectraCure P18 system

Primary Outcome Measures :
  1. Number of participants with treatment related adverse events as assesses by CTCAE v4.0 related to protocol therapy. [ Time Frame: Within 4 weeks of treatment in each cohorte ]
    Dose limiting toxicities are defined as grade 3 non-hematologic or grade 4 hematologic toxicities that are possibly, probably or definitely related to PDT.

Secondary Outcome Measures :
  1. Damage to the periprostatic tissues including the rectal wall mediated by PDT [ Time Frame: 5-9 days following PDT ]
    Potential damage to the periprostatic tissue will be evaluated by contrast-enhanced and not-contrast enhanced MRI .

  2. Performance of SpectraCure P18 system [ Time Frame: Dose-volume histograms will be evaluated at month 12 ]
    Performance of the SpectraCure P18 system will be evaluated by light dose-volume histograms for the light dose coverage

  3. Adequacy of effectiveness [ Time Frame: Within 1 week of treatment ]
    Effectivity will be evaluated by MRI to determine the extent of necrosis in the prostate

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Males with recurrent prostate cancer
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Males > 18 years who have gone through external or internal, high dose rate (brachy) radiation therapy for localized prostate cancer with histopathologically verified local recurrence.
  2. Prostate volume less than 50 cm3 defined by transrectal ultrasound
  3. Subject not eligible for surgery or curative radiotherapy
  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  5. Expected survival ≥ 8 months
  6. Sufficient bone marrow reserve as indicated by; granulocyte count ≥ 1500/mm3, platelet count ≥ 100,000/mm3
  7. Adequate renal function as defined by creatinine ≤ 1.5 mg /dl
  8. Adequate hepatic function, based on a total bilirubin ≤ 1.5 mg/dl, serum glutamate-oxaloacetate transaminase (SGOT) ≤ 3 times the upper limit of normal, and alanine transaminase (ALT) ≤ 3 times the upper limit of normal
  9. Signed Informed Consent

Exclusion Criteria:

  1. Patients with locally advanced (AJCC 7th edition T3/T4) or metastatic disease
  2. Patients who have been treated with seed implantation brachytherapy
  3. Gleason score ≥ 8 at initial diagnosis
  4. Less than 1 week since surgery (excluding minimal procedures, e.g. vascular access device insertion)
  5. Concomitant infection
  6. Subjects with other severe concurrent disease that in the judgement of the investigator would make the subject inappropriate for entry into this study
  7. Mental incapacity or psychiatric illness that would interfere with the subject's ability to understand and give informed consent or to complete follow-up visits according to the judgement of the investigator
  8. Contraindication for photosensitizer
  9. Porphyria or other diseases exacerbated by light
  10. Known hypersensitivity to verteporfin for injection (VFI) or to any of the excipients
  11. Known allergies to porphyrins
  12. Tumours known to be eroding into a major blood vessel in or adjacent to the illumination site
  13. On-going therapy with a photosensitizing agent
  14. Enrolment in another therapeutic clinical study within 3 months prior to randomization and throughout the study.
  15. Subjects with a history of CTCAE v4 grade 3 or greater or persistent (>1 separate episode or symptoms lasting more than 3 months after initiation of medical intervention) grade 2 proctitis attributed to radiation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03067051

Layout table for location contacts
Contact: Johannes Swartling +46 (0) 46 16 20 70

Layout table for location information
United States, Pennsylvania
Keith Cengel Not yet recruiting
Philadelphia, Pennsylvania, United States, 19104-6205
Contact: Keith Cengel, MD         
Contact: Sally Mcnulty, RN         
Canada, Ontario
Princess Margaret Cancer Centre Recruiting
Toronto, Ontario, Canada, ON M5G 2M9
Contact: Neil Fleshner, MD         
United Kingdom
Reader in Urology, University College London & Honorary Consultant Urological Surgeon, University College London Hospitals Trust Recruiting
London, United Kingdom, W1W 7TS
Contact: Caroline Moore, MD         
Contact: Rebecca Scott, RN         
Sponsors and Collaborators
SpectraCure AB
Layout table for additonal information
Responsible Party: SpectraCure AB Identifier: NCT03067051    
Other Study ID Numbers: SPC11-01-110
First Posted: March 1, 2017    Key Record Dates
Last Update Posted: May 13, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases
Photosensitizing Agents
Dermatologic Agents